Abstract
Background Synucleinopathies include Parkinson’s disease (PD), Lewy body dementia (LBD) and Multiple system atrophy (MSA). Most studies of synucleinopathies rely on immunoassays to quantify total or oligomeric alpha synuclein. Immunoassay results are variable due to the inconstant nature of antibodies and different studies found higher, lower or equal levels of alpha synuclein between PD and control patients in biological matrixes. Mass spectrometry, has less inherent variability.
Methods Therefore, we developed the first reliable and validated mass spectrometry method to quantify synuclein proteoforms in human plasma using liquid chromatography coupled to mass spectrometry with multiple reaction monitoring mode (LC-MRM) mass spectrometry,
Results The study followed European and International guidelines (Food and Drug administration and European Medicines Agency) and paves the way for precise multiplex quantitation of synucleinopathies. Using a cohort of 143 patients with synucleinopathies and controls we found a peptide ratio and combination between α-syn EQVTNVGGAVVTGVTAVAQK and α/β-syn EGVLYVGSK peptides that discriminated PD patients from the other diseases (LBD, MSA and controls). The sensitivity and specificity (Area Under ROC Curve) of the method to distinguish between patients with PD and control patients was 0.84 and 0.76 (0.787), for PD vs LBD the values were 0.7 and 0.68 (0.743), and 0.85 and 0.85 (0.831) for PD vs MSA.
Conclusions The developed and validated LC-MRM method presented here could be used in clinical to discriminate PD from other synucleinopathies and control patient.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The authors have no conflict of interest to report. Mass spectrometry experiments were carried out using the facilities of the Montpellier Proteomics Platform (PPM-PPC, BioCampus Montpellier). This article has been written in the context of the innovation center of Shimadzu Europa GmbH.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All the participants gave their written consent to be enrolled in the study which was approved by the Montpellier University Hospitals regional Ethics Committee. Authorization to handle personal data was granted by the French Data Protection Authority (CNIL).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
